نتایج جستجو برای: nonresponder
تعداد نتایج: 528 فیلتر نتایج به سال:
INTRODUCTION HIV-infected patients are affected significantly more frequently by all types of lymphoma, with diffuse large B-cell lymphoma (DLBCL) as the most prevalent histological type. Since the introduction of combination antiretroviral therapy (cART) morbidity and mortality of DLBCL has been markedly reduced, which is primarily interpreted as a result of the drug-mediated immune reconstitu...
Twelve of 303 per-protocol patients were nonresponders in a 12-week versus 24-week treatment study of hepatitis C virus (HCV) genotype 2/3 infection. The nonresponders had significantly lower interferon concentrations, as well as significantly greater mean age, body mass index, and viral load. Suboptimal drug concentrations may thus contribute to lack of response to therapy in patients with inf...
We determined the MHC restriction of CTL responses to five individual influenza virus proteins. Four viral proteins failed to be recognized in conjunction with three of the five class I alleles of the H-2k and H-2d haplotypes, while the fifth was recognized only in conjunction with a single allele. This indicates that there is a significant chance that a given class I allele will be associated ...
A series of recent experiments from our laboratory have focused on the demonstration and characterization of a relatively IgE class-specific, nonantigen-specific, cellular suppressor mechanism involved in the murine IgE antibody response to allergens not controlled by H-2-1inked immune response (Ir) genes (1, 2). Such a suppressor T-cell mechanism was initially demonstrated indirectly by admini...
Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved by the US FDA for treatment of adults with moderate-to-severe plaque psoriasis who are candidates systemic therapy or phototherapy. Deucravacitinib was significantly more efficacious than placebo apremilast and well tolerated in previous reports from phase 3 POETYK PSO-1 trial. Here, we examin...
Abstract Background Prior exposure to biologics can influence response subsequent lines of advanced therapies. Previous analyses showed that patients who did not achieve clinical following 10 weeks ozanimod treatment in the phase 3 True North (TN) study benefited from extended induction with open-label TN extension (OLE) study. As impact prior biologic on outcomes is unknown, aim this analysis ...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید